Early morning hyperglycemia is sometimes called the “dawn phenomenon.” Left untreated, it can drive poorer outcomes. How can ...

The bi-weekly formulation of GLP-1 has ... whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Introduction Southeast Asia and North America are the native home of black seed oil, also known as black cumin seed, Nigella sativa, and ...

The mechanisms underlying blockage are not well understood; it is speculated that a complex interaction can occur between the plastic material used in the IIS, the insulin formulation used ...

Managing stress and maintaining overall health can be quite challenging in today’s fast-paced world. Many people turn to ...

Favorable capital market conditions last week enabled the company to raise over $15 million from secondary offerings, and the proceeds allow the Company to fund fully the costs of this upcoming ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkinson’s Disease is now fully funded. Favorable capital market conditions last week enabled the company to raise ...

Insulin resistance, which impacts millions ... and others have noted that the formulation is different than the original natural product. Additionally, Thorne Berberine may not work for everyone ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Good day and welcome to the Vertex Pharmaceuticals third-quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to ...